PAU7 Antibody

What is PAX7 and why is it significant in research?

PAX7 (Paired box 7) is a protein encoded by the gene PAX7 in humans. The protein is approximately 55.1 kilodaltons in mass and may also be known as HUP1, PAX7B, RMS2, paired box protein Pax-7, and PAX7 transcriptional factor . PAX7 is a critical transcription factor involved in satellite cell specification and maintenance in skeletal muscle development and regeneration. It serves as an essential marker for satellite cells and plays crucial roles in muscle homeostasis, making it significant for research in developmental biology, regenerative medicine, and certain cancers like rhabdomyosarcoma.

What are the different types of PAX7 antibodies available for research?

There are numerous PAX7 antibodies available across different suppliers, with Biocompare listing 567 PAX7 antibodies from 28 suppliers . These include:

When selecting a PAX7 antibody, researchers should consider the host species, clonality, validated applications, and the specific experimental requirements.

How can I properly validate a PAX7 antibody before use in critical experiments?

Proper antibody validation is essential for generating reliable research data. A systematic approach includes:

• CRISPR/Cas9 Knockout Validation: Generate PAX7 knockout cell lines using CRISPR/Cas9 and compare antibody performance between parental and knockout lines .

• Proteomics Database Screening: Use databases like PaxDB to identify cell lines with high PAX7 expression as positive controls .

• Multi-application Testing: Validate the antibody in multiple applications (Western blot, immunoprecipitation, immunofluorescence) to ensure consistent performance.

• Cell Line Expression Screening: Perform quantitative immunoblots on multiple cell lines to identify those with highest PAX7 expression levels .

• Blocking Peptide Analysis: Pre-incubate the antibody with a specific PAX7 peptide to confirm binding specificity.

This validation pipeline is scalable, relatively inexpensive, and provides comprehensive confirmation of antibody specificity .

How do fixation methods affect PAX7 epitope recognition in immunostaining experiments?

Fixation methods significantly impact PAX7 epitope accessibility and recognition:

• Fixative Comparison: Different fixatives affect epitope recognition differently. Research shows that:

  • 4% paraformaldehyde (PFA) preserves protein structure through cross-linking

  • Methanol (chilled at -20°C) tends to denature proteins, potentially exposing different epitopes

• Epitope Masking: The paired box domain of PAX7 may be particularly sensitive to fixation-induced conformational changes.

• Optimization Protocol:

  • Test both PFA and methanol fixation for 10 minutes each

  • Include appropriate permeabilization steps (0.3% Triton X-100 for PFA-fixed samples)

  • Perform parallel staining of differently fixed samples using the same antibody concentration (recommended starting concentration: 2 μg/ml)

  • Incubate primary antibodies overnight at 4°C for optimal binding

Always include suitable controls when evaluating fixation effects, such as known PAX7-expressing and non-expressing cells.

What are the best approaches for troubleshooting weak or non-specific PAX7 antibody signals?

When encountering weak or non-specific PAX7 antibody signals, implement this systematic troubleshooting approach:

• Antibody Validation: First verify antibody specificity using knockout controls:

  • Generate CRISPR/Cas9 knockout of PAX7 in a cell line expressing the protein

  • Compare staining patterns between parental and knockout cells

  • Use a mosaic culture system with differentially labeled wild-type and knockout cells for direct comparison

• Signal Enhancement Strategies:

  • Optimize primary antibody concentration through titration

  • Extend incubation time (overnight at 4°C often improves specific binding)

  • Test different blocking buffers (5% BSA in TBS with 0.3% Triton X-100 is often effective)

  • Consider signal amplification systems for low abundance targets

• Background Reduction Techniques:

  • Increase washing steps (3 × 10 minutes recommended)

  • Pre-absorb antibodies with cell/tissue lysates lacking PAX7

  • Use gradient gel electrophoresis (5-16%) for better resolution in Western blotting

  • Optimize transfer conditions and confirm with Ponceau staining

Remember that PAX7 is expressed at relatively low levels in most tissues, which may necessitate sensitive detection methods .

How can I optimize immunoprecipitation protocols specifically for PAX7?

Optimizing immunoprecipitation for PAX7 requires careful consideration of protein characteristics and interaction dynamics:

• Lysis Buffer Selection:

  • Use buffers that preserve protein structure while effectively solubilizing nuclear proteins

  • Recommended starting composition: 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1% NP-40 or Triton X-100, with protease inhibitors

  • Consider adding DNase I to reduce chromatin-mediated background

• Antibody Selection Criteria:

  • Choose antibodies specifically validated for immunoprecipitation

  • Identify high-expressing cell lines through quantitative immunoblot screening

  • Test multiple antibodies recognizing different epitopes

• Protocol Optimization:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Titrate antibody-to-lysate ratios (typical range: 2-5 μg antibody per mg of protein)

  • Optimize incubation time and temperature (overnight at 4°C is standard)

  • Implement stringent washing steps to reduce background while preserving specific interactions

• Validation Strategy:

  • Confirm successful immunoprecipitation by Western blotting a portion of the IP product

  • Include isotype control antibody as negative control

  • If possible, include PAX7 knockout lysate as specificity control

What considerations are necessary when using PAX7 antibodies for co-localization studies?

When conducting co-localization studies with PAX7 antibodies, several critical factors must be addressed:

• Antibody Compatibility Assessment:

  • Ensure antibodies for co-staining are raised in different host species

  • If using multiple mouse monoclonals, consider sequential staining with direct labeling

  • Test cross-reactivity of secondary antibodies

• Imaging Considerations:

  • Use confocal microscopy with appropriate channel separation to minimize bleed-through

  • Consider spectral unmixing for closely overlapping fluorophores

  • Employ deconvolution to improve resolution of nuclear staining

• Technical Validation:

  • Include single-stained controls to establish baseline signals

  • Use cells expressing fluorescent protein tags (e.g., LAMP1-YFP, LAMP1-RFP) for control of co-localization methodology

  • Create mosaic cultures of wild-type and knockout cells on the same coverslip for direct comparison

• Quantitative Analysis:

  • Apply appropriate co-localization algorithms (Pearson's coefficient, Manders' overlap)

  • Perform rigorous statistical analysis across multiple fields and biological replicates

  • Use single-pixel analysis rather than whole-image metrics for nuclear transcription factors

Remember that PAX7 is primarily nuclear, so co-localization with cytoplasmic or membrane proteins should be interpreted cautiously.

How should I quantify PAX7 expression levels in tissue samples?

Accurate quantification of PAX7 expression requires rigorous methodological approaches:

• Western Blot Quantification:

  • Use total protein staining (e.g., REVERT) to normalize loading rather than single housekeeping proteins

  • Employ fluorescence-based detection systems (e.g., LI-COR Odyssey) for linear quantification

  • Include standard curves with recombinant PAX7 protein for absolute quantification

  • Analyze with appropriate software (e.g., LI-COR Image Studio Lite)

• Immunohistochemistry Quantification:

  • Establish standardized staining protocols with consistent antibody concentrations

  • Use automated image analysis software to quantify:

    • Percentage of PAX7-positive nuclei

    • Staining intensity (weak, moderate, strong)

    • Nuclear vs. cytoplasmic localization

  • Apply tissue microarrays for high-throughput analysis across multiple samples

• Flow Cytometry Approaches:

  • Optimize permeabilization protocols for nuclear protein detection

  • Use median fluorescence intensity (MFI) for relative quantification

  • Include appropriate controls (isotype, FMO, PAX7-knockout cells)

• RT-qPCR Correlation:

  • Correlate protein expression with mRNA levels for comprehensive analysis

  • Use absolute quantification with standard curves for precise measurement

What are the species cross-reactivity considerations for PAX7 antibodies?

Species cross-reactivity is a crucial consideration when selecting PAX7 antibodies:

• Evolutionary Conservation Analysis:

  • PAX7 shows high conservation across mammals, with orthologs found in canine, porcine, monkey, mouse, and rat species

  • The paired box domain typically shows higher conservation than other regions

• Cross-Reactivity Testing Protocol:

  • Verify antibody reactivity across species using:

    • Western blotting of tissue/cell lysates from different species

    • Immunostaining of fixed tissues from target species

    • Flow cytometry of cells from various species

• Species-Specific Optimization Table:

• Validation Strategy:

  • Generate species-specific knockout controls where possible

  • Use peptide competition assays with species-specific peptides

  • Include positive control tissues known to express PAX7 in the target species

How can I distinguish between PAX7 and other PAX family members with antibodies?

The PAX family contains nine members (PAX1-9) with structural similarities that can complicate specific detection:

• Sequence Alignment Strategy:

  • PAX3 shares highest homology with PAX7 and poses greatest risk of cross-reactivity

  • Select antibodies targeting unique regions outside the conserved paired box domain

  • Verify epitope specificity through sequence alignment analysis

• Experimental Validation Approach:

  • Test antibody against lysates from cells overexpressing different PAX family members

  • Perform immunodepletion studies to assess cross-reactivity

  • Use CRISPR/Cas9 knockout of PAX7 as definitive negative control

• Multi-antibody Protocol:

  • Employ multiple antibodies targeting different PAX7 epitopes

  • Compare staining patterns to identify consensus versus divergent signals

  • Include PAX family co-staining to assess potential overlap

• Application-specific Considerations:

  • Western blotting: PAX7 (55.1 kDa) can be distinguished from other PAX family members by molecular weight

  • Immunostaining: Compare with known expression patterns of PAX family members

  • ChIP: Use sequence-specific validation of immunoprecipitated DNA regions

How can PAX7 antibodies be utilized in single-cell analysis technologies?

PAX7 antibodies are increasingly valuable in cutting-edge single-cell analysis technologies:

• Single-Cell Flow Cytometry Applications:

  • Optimize nuclear permeabilization protocols for intracellular PAX7 detection

  • Combine with surface markers for comprehensive cellular phenotyping

  • Implement index sorting to correlate PAX7 expression with downstream analysis

• Mass Cytometry (CyTOF) Integration:

  • Metal-conjugated PAX7 antibodies enable high-dimensional analysis

  • Combined profiling of PAX7 with up to 40 additional protein markers

  • Protocol considerations:

    • Thorough fixation and permeabilization optimization

    • Careful titration of metal-conjugated antibodies

    • Inclusion of barcoding for batch processing

• Spatial Transcriptomics Correlation:

  • Pair PAX7 immunostaining with spatial transcriptomics platforms

  • Correlate protein expression with transcriptional profiles in tissue context

  • Implement sequential immunofluorescence for multiplexed protein detection

• Single-Cell Sequencing Integration:

  • Use PAX7 antibodies for cell sorting prior to single-cell RNA-seq

  • Employ CITE-seq approaches with oligo-tagged PAX7 antibodies

  • Analyze PAX7+ cell heterogeneity through clustering analysis

These advanced applications require rigorous antibody validation using knockout controls to ensure specificity at the single-cell level .

What are the considerations for using PAX7 antibodies in chromatin immunoprecipitation (ChIP) experiments?

ChIP experiments with PAX7 antibodies present unique challenges requiring specific methodological approaches:

• Antibody Selection Criteria:

  • Choose antibodies validated specifically for ChIP applications

  • Test multiple antibodies targeting different PAX7 epitopes

  • Consider the accessibility of epitopes in chromatin-bound PAX7

• Protocol Optimization Strategies:

  • Cross-linking optimization: Test varying formaldehyde concentrations (0.5-2%)

  • Sonication parameters: Adjust to obtain chromatin fragments of 200-500 bp

  • Washing stringency: Balance between reducing background and maintaining specific interactions

  • Elution conditions: Consider native elution with competing peptides for specialized applications

• Validation Approaches:

  • Perform ChIP-qPCR on known PAX7 target genes before proceeding to genome-wide analysis

  • Include PAX7 knockout or knockdown cells as negative controls

  • Use species-inappropriate antibodies or IgG as technical negative controls

• Data Analysis Considerations:

  • Compare binding patterns with published PAX7 motifs

  • Integrate with transcriptomic data to correlate binding with gene expression

  • Consider PAX7 co-factors that may influence binding patterns

• Advanced Applications:

  • ChIP-seq for genome-wide PAX7 binding sites

  • CUT&RUN for improved signal-to-noise ratio

  • ChIP-SICAP to identify chromatin-associated PAX7 protein complexes

How should PAX7 antibodies be used in the identification and characterization of satellite cells?

PAX7 is the definitive marker for satellite cells, making PAX7 antibodies essential tools in satellite cell research:

• Isolation Protocol Optimization:

  • FACS sorting strategy:

    • Optimize nuclear permeabilization without compromising cell viability

    • Combine PAX7 staining with surface markers (integrin-α7, VCAM-1)

    • Include viability dye to exclude dead cells with non-specific binding

  • Magnetic bead-based isolation:

    • Consider two-step isolation with surface markers followed by PAX7 enrichment

    • Validate purity by immunostaining of sorted populations

• In Situ Identification Strategy:

  • Fresh tissue preparation:

    • Optimize fixation (test both 4% PFA and methanol)

    • Use antigen retrieval for improved detection

  • Single fiber isolation:

    • Maintain satellite cell attachment during processing

    • Combine PAX7 with activation markers (MyoD, Myf5) and proliferation markers

• Quantification Approaches:

  • Standard metrics:

    • PAX7+ cells per fiber

    • PAX7+ cells per cross-sectional area

    • Proportion of activated (PAX7+/MyoD+) versus quiescent (PAX7+/MyoD-) cells

  • Automated analysis:

    • Develop algorithms for unbiased quantification

    • Implement machine learning for complex phenotype identification

• Functional Correlation:

  • Co-stain with markers of satellite cell states

  • Correlate PAX7 expression levels with regenerative capacity

  • Track PAX7+ cells through lineage tracing experiments

What are the most common sources of false-positive signals with PAX7 antibodies and how can they be mitigated?

False-positive signals with PAX7 antibodies can undermine research findings. Understanding and mitigating these issues is essential:

• Cross-reactivity Issues:

  • With PAX family members: Verify antibody specificity through knockout controls

  • With unrelated proteins: Test antibodies in PAX7-null systems and through peptide competition assays

  • Mitigation strategy: Use multiple antibodies targeting different epitopes and confirm consistent patterns

• Technical Artifacts:

  • Non-specific binding to necrotic tissue: Include viability assessment

  • Edge effects in tissue sections: Exclude tissue edges from analysis

  • Fixation-induced autofluorescence: Use appropriate quenching methods

  • Mitigation strategy: Include appropriate blocking steps and optimize antibody concentration

• Validation Controls:

  • Generate PAX7 knockout cell lines using CRISPR/Cas9

  • Create mosaic cultures of wildtype and knockout cells for direct comparison

  • Use cell lines with defined PAX7 expression profiles as positive/negative controls

• Application-specific Precautions:

  • Western blotting: Confirm band size (55.1 kDa) and include knockout lysate control

  • Immunofluorescence: Compare PFA and methanol fixation results

  • Flow cytometry: Use fluorescence minus one (FMO) controls to set gates accurately

What quality control measures should be implemented for long-term reproducibility with PAX7 antibodies?

Ensuring long-term reproducibility requires systematic quality control procedures:

• Antibody Characterization Documentation:

  • Maintain detailed records of antibody validation experiments

  • Document lot-to-lot testing results and variations

  • Create a laboratory validation database accessible to all researchers

• Standardized Protocols:

  • Develop detailed standard operating procedures (SOPs) for each application

  • Include all buffer compositions, incubation times/temperatures, and control samples

  • Implement checklist system for critical protocol steps

• Reference Standards:

  • Maintain frozen aliquots of validated positive control lysates/cells

  • Create standard curves for quantitative applications

  • Preserve exemplar images of expected staining patterns

• Regular Performance Verification:

  • Test new antibody lots against previous lots

  • Perform periodic knockout validation checks

  • Monitor signal-to-noise ratios across experiments

• Data Management System:

  • Implement a consistent file naming and organization system

  • Store raw unprocessed data alongside analyzed results

  • Include metadata on antibody lots, protocol versions, and operator information

This comprehensive quality control approach helps identify and address variables that could affect experimental outcomes.